Table 2.
Potential lncRNA-related therapy.
| Target | Adjustment | Cell Type | Proposed molecular mechanisms | Correlation | Reference |
|---|---|---|---|---|---|
| LncRNA NEAT1 | Downregulate | — | Interaction with miR-377-3p | Inhibits apoptosis of OA chondrocytes | (117) |
| LncRNA NEAT1 | Upregulate | MSC | Regulated Sesn2/Nrf2 by interacting with miR-122-5p | Induces the proliferation and autophagy of chondrocytes, inhibits apoptosis | (95) |
| LncRNA XIST | Downregulate | — | MiR-211/CXCR4 | Inhibits IL-1β-treated chondrocytes cell multiplication and promotes apoptosis | (76) |
| LncRNA XIST | Downregulate | C28/I2 cells | Regulated STAT3 by interacting with MiR-130a | Inhibits inflammation and ECM degradation | (121) |
| CILinc02 | Downregulate | OA primary cells | Increases the expression of MMP-1 and MMP-13 proteins | Inhibits IL-1, IL-6, IL-17-induced inflammatory responses | (119) |
| LncRNA HOTAIR | Downregulate | — | PTEN/PI3K/AKT pathways | Inhibits OA inflammation | (72) |
| LncRNA ZFAS1 | Upregulate | OA primary cells | Interaction with MiR-1323 | Promotes chondroid proliferation and inhibits oxidative stress | (113) |
| LncRNA PILA | Downregulate | OA primary cells | Regulated TAK1 by methylation | Inhibits chondrocytes apoptosis and ECM breakdown | (123) |
| KLF3-AS1 | Upregulate | Human MSCs | Regulated PI3K/Akt/mTOR pathway by Interaction with YBX1 | Represses autophagy and apoptosis of IL-1β-treated chondrocytes | (124) |
| MM2P | Upregulate | RAW264.7 cells | Regulated Col1a2 and Acan | Promoted chondrocyte differentiation and function | (125) |
| LncRNA H19 | Downregulate | Primary FLSs | Regulated TIMP2 by interacting with miR-106-5p | Promotes chondrocytes proliferation and migration and inhibits ECM degradation | (91) |
| LncRNA GAS5 | Upregulate | OA primary cells | Regulated PVT1 | ECM degradation and apoptosis | (68–70) |
| LncRNA HAS2-AS1 | Downregulate | — | Regulated SIRT1 | Inhibition of HA accumulation | (109–111) |
| LncRNA MALAT1 | Downregulate | OA primary cells | Regulated Wnt/β-catenin/NF-κB pathway | Represses autophagy and apoptosis of IL-1β-treated chondrocytes | (106) |
| LncRNA NKILA | Upregulate | OA primary cells | Regulated growth factor-β1/SMAD2/3 pathway | Reduced cartilage tissue degradation and MMP-13 expression | (71) |
| LncRNA MEG3 | Upregulate | — | Regulated P2X3 | Inhibits IL-1β, IL-6, IL-8 and TNF-α induced inflammatory responses | (120) |
NEAT1, Nuclear Enriched Abundant Transcript 1; OA, OA; MSC, Mesenchymal Stem Cell; CXCR4, Motif Chemokine Receptor 4; ECM, cell-extracellular matrix; MMP-1, Matrix Metallopeptidase 1; MMP-13, Matrix Metallopeptidase 13; PTEN, Phosphatase and tensin homolog; PI3K, Phosphatidylinositol 3 kinase; AKT, Protein Kinase B; TAK1, TGF-β-activated kinase 1; YBX1, Recombinant Y-Box Binding Protein 1; IL-1β, Interleukin-1β.